ArticleBritish journal of cancer2018
Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Pooled it
- Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis.Frontiers in endocrinology · 2022Pooled it
- Review
- Reproductive Challenges in Mutated BRCA Gene Carriers: A Narrative Review.Current issues in molecular biology · 2026Review
- Assisted Reproductive Technology in Breast and Gynecologic Malignancies: Cancer Risk, Fertility Preservation, and Post-Treatment Reproductive Outcomes.Journal of clinical medicine · 2026Review
- Treatment of infertility and risk of breast cancer among women with a BRCA pathogenic variant: a matched case-control study.BMC cancer · 2025Article
- Conception and Concern: A Review of Breast Cancer Risk in Assisted Reproductive Technology.International journal of biological sciences · 2025Review
- Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?ESMO open · 2024Review
- Outcomes and the effect of PGT-M in women with hormone-related hereditary tumor syndrome.Frontiers in oncology · 2024Article
- What Is Known about Breast Cancer in Young Women?Cancers · 2023Review
- Review
- Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants inCancers · 2022Review
- Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting.BMC medicine · 2021Article
- A Review of Modifiable Risk Factors in Young Women for the Prevention of Breast Cancer.Breast cancer (Dove Medical Press) · 2021Review
- Counseling young women with early breast cancer on fertility preservation.Journal of assisted reproduction and genetics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effect of in vitro fertilisation (IVF) on breast cancer risk for BRCA1/2 mutation carriers is rarely examined. As carriers may increasingly undergo IVF as part of preimplantation genetic diagnosis (PGD), we examined the impact of ovarian stimulation for IVF on breast cancer risk in BRCA1/2 mutation carriers.
methodsThe study population consisted of 1550 BRCA1 and 964 BRCA2 mutation carriers, derived from the nationwide HEBON study and the nationwide PGD registry. Questionnaires, clinical records and linkages with the Netherlands Cancer Registry were used to collect data on IVF exposure, risk-reducing surgeries and cancer diagnosis, respectively. Time-dependent Cox regression analyses were conducted, stratified for birth cohort and adjusted for subfertility.
resultsOf the 2514 BRCA1/2 mutation carriers, 3% (n = 76) were exposed to ovarian stimulation for IVF. In total, 938 BRCA1/2 mutation carriers (37.3%) were diagnosed with breast cancer. IVF exposure was not associated with risk of breast cancer (HR: 0.79, 95% CI: 0.46-1.36). Similar results were found for the subgroups of subfertile women (n = 232; HR: 0.73, 95% CI: 0.39-1.37) and BRCA1 mutation carriers (HR: 1.12, 95% CI: 0.60-2.09). In addition, age at and recency of first IVF treatment were not associated with breast cancer risk.
conclusionNo evidence was found for an association between ovarian stimulation for IVF and breast cancer risk in BRCA1/2 mutation carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.